Innovacell Co., Ltd. is a Japanese clinical-stage biopharmaceutical company focused on the research, development, and commercialization of autologous cell therapy products (regenerative medicine products) targeting incontinence disorders, specifically fecal and urinary incontinence. The company operates three pipelines—ICEF15 (urge fecal incontinence), ICEF16 (passive fecal incontinence), and ICES13 (stress urinary incontinence)—based on proprietary skeletal muscle-derived myoblast technology developed by its wholly owned Austrian subsidiary, Innovacell GmbH. Its most advanced pipeline, ICEF15, is currently in an international Phase III clinical trial spanning Japan and Europe, with U.S. site additions underway, and the company employs a 'Global Aggregation Model' to source, develop, and commercialize promising cell therapy assets worldwide.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Innovacell Co., Ltd. is a Japanese clinical-stage biopharmaceutical company focused on the research, development, and commercialization of autologous cell therapy products (regenerative medicine products) targeting incontinence disorders, specifically fecal and urinary incontinence. The company operates three pipelines—ICEF15 (urge fecal incontinence), ICEF16 (passive fecal incontinence), and ICES13 (stress urinary incontinence)—based on proprietary skeletal muscle-derived myoblast technology developed by its wholly owned Austrian subsidiary, Innovacell GmbH. Its most advanced pipeline, ICEF15, is currently in an international Phase III clinical trial spanning Japan and Europe, with U.S. site additions underway, and the company employs a 'Global Aggregation Model' to source, develop, and commercialize promising cell therapy assets worldwide.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →